BioNeutral Group presents lab results for antimicrobial used on swine flu
NEWARK, N.J. BioNeutral Group on Thursday announced that independent lab test results conducted at Microbiotest of Sterling, Va., demonstrated that its Ygiene Consumer Grade Antimicrobial totally eradicated the novel H1N1 virus within 20 seconds of contact.
“We are well on our way to achieving our objective to have the fastest-acting, least-expensive, longest-lasting, simple-to-use, green formulations to eliminate swine flu from home, office, schools and public gathering places,” stated Andy Kielbania, chief scientist for Bioneutral Group. “This mild formulation can come into daily contact with skin and clothing, providing added protection against H1N1 and other dangerous organisms for the general population and the broader healthcare sector, as well.”
Ygiene is one of a few antimicrobials actually tested against the specific H1N1 virus, the company stated.
The formulation will be presented to the U.S. Environmental Protection Agency for regulatory approval, the company stated.
As seen on shelf at Walgreens, having a major pharma player like Bayer HealthCare field what essentially is a hangover-relief product adds credibility, not to mention a little more shelf presence, to similar products like Living Essentials’ Chaser Plus.
XenaCare receives ‘Best New Product’ award at conference
DELRAY BEACH, Fla. XenaCare Holdings on Monday announced that its stage 2 pain reliever, Cobroxin, has won the award for “Best New Product,” sponsored by Drug Store News, at the recent ECRM Health held in Miami.
“It is an honor to have Cobroxin chosen as the best new product at ECRM,” stated Frank Rizzo, president of XenaCare. “This award … supports our belief that Cobroxin will soon become the preferred alternative to current opiate and acetaminophen-based analgesics,” he concluded.
Retailer attendees nominate and vote on “Best New Product” at the show.
Cobroxin is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation clinically proven to treat moderate to severe (Stage 2) pain. Recently, XenaCare Holdings was awarded the exclusive license for marketing and distributing Cobroxin within the United States.
As part of Drug Store News’ sponsorship of the award, XenaCare Holdings will receive a full-page advertisement in an upcoming issue of Drug Store News.